Cargando…

Antivenom availability, delays and use in Australia

Antivenom is the main treatment for snake envenoming and there are ongoing concerns about availability in resource poor regions of the world. However, effective antivenom treatment for snake envenoming requires more than improved availability of safe and efficacious antivenoms. Most importantly, ant...

Descripción completa

Detalles Bibliográficos
Autor principal: Isbister, Geoffrey K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9747507/
https://www.ncbi.nlm.nih.gov/pubmed/36523639
http://dx.doi.org/10.1016/j.toxcx.2022.100145
_version_ 1784849615384739840
author Isbister, Geoffrey K.
author_facet Isbister, Geoffrey K.
author_sort Isbister, Geoffrey K.
collection PubMed
description Antivenom is the main treatment for snake envenoming and there are ongoing concerns about availability in resource poor regions of the world. However, effective antivenom treatment for snake envenoming requires more than improved availability of safe and efficacious antivenoms. Most importantly, antivenom must be administered as early as possible, and within 2–6 h of the bite in Australia. At the same time, it is also important that antivenom not be given to all patients indiscriminately with a suspected snakebite, because of the risk of anaphylaxis. Delays in the administration of antivenom are a significant impediment to effective antivenom treatment and can be divided into pre-hospital and in-hospital delays. These range from delays due to remoteness of snakebite, to delays in diagnosis and administration of antivenom once in hospital. In Australia, antivenom is readily available in most hospitals, and a large portion of patients present to hospital within 2 h of the bite. However, there is on average a further delay of 2.5 h before antivenom is administered. Early diagnosis with accurate bedside tests and rapid clinical assessment of patients with snakebite are key to improving the effective use of antivenom.
format Online
Article
Text
id pubmed-9747507
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-97475072022-12-14 Antivenom availability, delays and use in Australia Isbister, Geoffrey K. Toxicon X Article from Special Issue on Resource mapping for the management of snakebite envenomation, Edited by: Jose Maria Gutiérrez, Wuelton Monteiro, Hui Wen Fan, Abdulrazaq Habib, Kalana Maduwage, and Joao Ricardo Nickenig Vissoci Antivenom is the main treatment for snake envenoming and there are ongoing concerns about availability in resource poor regions of the world. However, effective antivenom treatment for snake envenoming requires more than improved availability of safe and efficacious antivenoms. Most importantly, antivenom must be administered as early as possible, and within 2–6 h of the bite in Australia. At the same time, it is also important that antivenom not be given to all patients indiscriminately with a suspected snakebite, because of the risk of anaphylaxis. Delays in the administration of antivenom are a significant impediment to effective antivenom treatment and can be divided into pre-hospital and in-hospital delays. These range from delays due to remoteness of snakebite, to delays in diagnosis and administration of antivenom once in hospital. In Australia, antivenom is readily available in most hospitals, and a large portion of patients present to hospital within 2 h of the bite. However, there is on average a further delay of 2.5 h before antivenom is administered. Early diagnosis with accurate bedside tests and rapid clinical assessment of patients with snakebite are key to improving the effective use of antivenom. Elsevier 2022-12-08 /pmc/articles/PMC9747507/ /pubmed/36523639 http://dx.doi.org/10.1016/j.toxcx.2022.100145 Text en © 2022 The Author https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article from Special Issue on Resource mapping for the management of snakebite envenomation, Edited by: Jose Maria Gutiérrez, Wuelton Monteiro, Hui Wen Fan, Abdulrazaq Habib, Kalana Maduwage, and Joao Ricardo Nickenig Vissoci
Isbister, Geoffrey K.
Antivenom availability, delays and use in Australia
title Antivenom availability, delays and use in Australia
title_full Antivenom availability, delays and use in Australia
title_fullStr Antivenom availability, delays and use in Australia
title_full_unstemmed Antivenom availability, delays and use in Australia
title_short Antivenom availability, delays and use in Australia
title_sort antivenom availability, delays and use in australia
topic Article from Special Issue on Resource mapping for the management of snakebite envenomation, Edited by: Jose Maria Gutiérrez, Wuelton Monteiro, Hui Wen Fan, Abdulrazaq Habib, Kalana Maduwage, and Joao Ricardo Nickenig Vissoci
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9747507/
https://www.ncbi.nlm.nih.gov/pubmed/36523639
http://dx.doi.org/10.1016/j.toxcx.2022.100145
work_keys_str_mv AT isbistergeoffreyk antivenomavailabilitydelaysanduseinaustralia